# The Cigna Group (CI) stock analysis and sentiment Canonical page: https://synoptiv.com/stock/CI Methodology: https://synoptiv.com/methodology Author: Synoptiv Research Engine Last analyzed: Sep 6, 2026 The Cigna Group (CI) last closed at $282.52, around the middle of its 52-week range of $239.51–$315.47. Composite market sentiment across 1 analysis is positive (+19 on a −100 to +100 scale), as of Sep 6, 2026. ## What the data says At $282.52, Cigna sits roughly in the middle-to-upper half of its 52-week range of $239.51 to $315.47 — about 18 percent above the low and around 10 percent below the high. That range spans a little over 30 percent from trough to peak, a fairly contained band for a full year of trading, and the current price sits inside it rather than at either edge. The market values the business at roughly $74.7 billion, or about 11.7 times trailing earnings and 8.4 times forward earnings; the gap between those two multiples reflects earnings expectations that sit above the trailing figure. Price to book stands at about 1.75. Net profit margin is thin at roughly 2.3 percent, which is characteristic of a business whose revenue base is very large relative to what falls to the bottom line, and revenue grew about 6.7 percent over the comparison period. The shares carry a dividend yield near 2.2 percent and a beta of 0.32, meaning the stock has historically moved considerably less than the broader market. Company-specific news over the period is sparse but substantive: an April update in which Cigna raised its outlook while flagging an exit from the individual exchange business and a strategic review of eviCore, a quarterly dividend declaration in the same month, and an August piece on its coverage approach. The remainder of the flow is only loosely connected — items on behavioral and virtual mental health services, a global health awareness event, and broad market commentary on value stocks and biotech that mention the sector rather than the company itself. On balance, the coverage leans more toward the wider healthcare and market backdrop than toward developments at Cigna directly. ## About The Cigna Group The Cigna Group is a U.S. health services and insurance company headquartered in Bloomfield, Connecticut. It traces its roots to 1792 and adopted its current name in 2023, having previously operated as Cigna Corporation. The business is organized into two segments: Evernorth Health Services and Cigna Healthcare. Evernorth Health Services covers pharmacy benefit management and related specialty and care services, including drug claim processing, retail pharmacy network administration, benefit design and formulary management, drug utilization review, home delivery and specialty pharmacy, specialty pharmaceutical distribution, and clinical care programs. Cigna Healthcare provides medical and related coverage in the United States and internationally, spanning employer plans, individual and family plans, behavioral health, dental, pharmacy management, stop-loss insurance, and health benefits for globally mobile individuals and employees of multinational organizations. The company also maintains other operations such as corporate-owned life insurance, reinsurance, and run-off businesses. Products reach customers through brokers and consultants, direct sales to employers, unions, and other groups, and public and private exchanges. ## Company profile - Symbol: CI - Exchange: NYSE - Security type: Stock - Sector: Healthcare - Industry: Healthcare Plans - Composite sentiment: positive (19 on a -100 to +100 scale) ## Key statistics | Metric | Value | | --- | ---: | | Market capitalization | $74.65B | | Enterprise value | $99.56B | | Trailing P/E | 11.68 | | Forward P/E | 8.44 | | Price to book | 1.75 | | Price to sales | 0.26 | | Dividend yield | 2.21% | | Beta | 0.32 | | Net margin | 2.27% | | Revenue growth | 6.70% | | Earnings growth | 10.20% | | 52-week high | $315.47 | | 52-week low | $239.51 | | Average volume | 1.66M | ## Related stocks - [CVS](https://synoptiv.com/stock/CVS) - [LH](https://synoptiv.com/stock/LH) - [DGX](https://synoptiv.com/stock/DGX) - [GH](https://synoptiv.com/stock/GH) - [LH](https://synoptiv.com/stock/LH) - [BTSG](https://synoptiv.com/stock/BTSG) - [DVA](https://synoptiv.com/stock/DVA) - [HNGE](https://synoptiv.com/stock/HNGE) - [CHE](https://synoptiv.com/stock/CHE) - [HIMS](https://synoptiv.com/stock/HIMS) ## Recent news - [Oracle, Adobe Results In Focus As Earnings Season Winds Down](https://seekingalpha.com/article/4943211-oracle-adobe-results-in-focus-as-earnings-season-winds-down) — Sep 5, 2026 - [Tracking Leon Cooperman's Omega Advisors Portfolio - Q2 2026 Update](https://seekingalpha.com/article/4942961-leon-cooperman-omega-advisors-portfolio-q2-2026-update) — Sep 3, 2026 - [UnitedHealth Stock Recovered Before Its Margins Did](https://www.trefis.com/articles/614234/unitedhealth-stock-recovered-before-its-margins-did/2026-09-03) — Sep 3, 2026 - [CVS Stock Has Left Its Peers Behind. Or Has It?](https://www.trefis.com/articles/614065/cvs-stock-has-left-its-peers-behind-or-has-it/2026-09-03) — Sep 3, 2026 - [The Bull Case For Cigna Group (CI) Could Change Following Its New Connected Benefits Platform Launch](https://finance.yahoo.com/healthcare/articles/bull-case-cigna-group-ci-221642179.html) — Sep 2, 2026 - [If You Invested $100 In Cigna Group Stock 20 Years Ago, You Would Have This Much Today](https://www.benzinga.com/news/26/09/61582734/if-you-invested-100-cigna-group-stock-20-years-ago-you-would-have-much-today) — Sep 2, 2026 - [How Is The Cigna Group’s Stock Performance Compared to Other Healthcare Plans](https://www.barchart.com/story/news/4395970/how-is-the-cigna-groups-stock-performance-compared-to-other-healthcare-plans) — Sep 2, 2026 - [2 of Wall Street’s Favorite Stocks Worth Investigating and 1 We Turn Down](https://finance.yahoo.com/markets/stocks/articles/2-wall-street-favorite-stocks-102023151.html) — Sep 2, 2026 - [Bill Ackman Backs Mark Cuban's Drug Pricing Model: These Healthcare Stocks Could Win—Or Lose](https://www.benzinga.com/news/health-care/26/09/61573089/ackman-cuban-drug-pricing) — Sep 2, 2026 - [FDA Says It Has Received 990 Adverse Event Reports Tied To Compounded Semaglutide And More Than 730 Tied To Compounded Tirzepatide; Establishes Import Alert For Compounded GLP-1 Active Pharmaceutical Ingredients](https://www.benzinga.com/government/26/09/61558178/fda-says-it-has-received-990-adverse-event-reports-tied-compounded-semaglutide-and-more-730-tied-com) — Sep 1, 2026 ## Frequently asked questions ### What is the current market sentiment for CI? As of Sep 6, 2026, The Cigna Group (CI) carries positive (+19 on a −100 to +100 scale) composite sentiment. The score fuses recent news tone, analyst recommendations, technical posture, insider and congressional activity, and market attention into a single figure. The full breakdown of each component is in the report. ### How has CI stock been performing? The Cigna Group last closed at $282.52, around the middle of its 52-week range of $239.51–$315.47. ### What is CI's market cap and valuation? The Cigna Group has a market capitalization of about $74.65B, a trailing P/E of 11.7, a dividend yield of 2.21%. ### What sector is CI in, and who are its competitors? The Cigna Group operates in the Healthcare sector, specifically Healthcare Plans. Comparable companies include CVS, LH, DGX, GH, LH. ### Where can I find a full analysis of CI? The full CI report covers the bull and bear cases, technical signals with entry, stop and target levels, complete financial statements, earnings history, insider and congressional trades, and the conditions that would invalidate the thesis. It requires a free account. ## Important information This page is generated from public market and company information. Data can be delayed, incomplete, or wrong. It is research and analysis, not financial advice. - [Methodology](https://synoptiv.com/methodology) - [Disclosures](https://synoptiv.com/disclosures) - [Full report](https://synoptiv.com/stock/CI/v/1) (account and access required)